New drug aims to supercharge immune system against prostate cancer
NCT ID NCT05361798
First seen Jun 27, 2026 · Last updated Jun 30, 2026 · Updated 2 times
Summary
This phase II trial tests whether adding an experimental drug called PDS01ADC to standard radiation and hormone therapy can help the immune system fight prostate cancer. About 65 men with high- or intermediate-risk prostate cancer that hasn't spread will take part. Some will get the drug after radiation, while others will receive only standard care, and researchers will compare immune responses.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PDS01ADC (an immunocytokine drug given as a shot under the skin)
What this could lead to
If it works, this could lead to a new combination treatment that helps the immune system better fight prostate cancer and reduces the chance of the cancer coming back.
What could go wrong
This is an early phase II trial with only 65 people, so results may not apply to everyone. The drug may cause side effects or fail to improve outcomes compared to standard therapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANCER OF PROSTATE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-••••